Summary:
A multicenter, randomized, double blind, placebo controlled, 8-week study to evaluate the safety and efficacy of nebivolol and valsartan given as a fixed-dose combination in patients with stage 1 or 2 essential hypertension.
Qualified Participants Must:
• Patients diagnosed with stage 1 or stage 2 essential hypertension
•
Be currently being treated for hypertension with at least 1 documented DBP value ≥ 90 and < 110 mm Hg in their medical history or at a recent time during prescreening
•
Be newly diagnosed with essential hypertension who have never received treatment
•
Have a mean sitting DBP > 95 and < 110 mm Hg at Screening (Visit 1)
•
Been previously diagnosed and who have not received antihypertensive medications for at least 4 weeks prior to Screening (Visit 1) must have a mean sitting DBP > 95 and < 110 mm Hg at screening (Visit 1)
•
Have a sitting pulse rate of at least 55 bpm at Screening
Qualified Participants May Receive:
Compensation for time and travel